Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib vs Omalizumab in Chronic Spontaneous Urticaria
NCT06042478Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Primary completion
- Sep 2025
- Countries
- 23
01
Overview
A Phase 3 trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Nov 2023; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06042478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042478.